zolbetuximab
astellas
[]
spotlight phase 3 trial in gastric and goj adeno presented at asco #gi23: zolbetuximab in addition to chemo improves pfs to 10.6 mo vs 8.7 with chemo alone and os to 18.2 mo vs 15.5 which are both significant! manageable toxicity. new 1st line standard of care in claudin 18.2+ 
Academic GI Cancer Centre in the City of London. Delivering evidence-based treatments and clinical trials to patients. Informing and education patients and HCPs